Drugs / 177Lu-RAD202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06824155 | Feb 2025 → Dec 2027 expected | cancer | Radiopharm Theranostics, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Radiopharm Theranostics, Ltd | Results Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗
Data available from the first three patients in the first cohort of the study show very significant tumor uptake in HER2 positive tumors. |
| 2025-03-17 | Radiopharm Theranostics, Ltd | Results New RAD202 data confirms positive tumor uptake radiopharmtheranostics.com ↗
Treatment with 177Lu-RAD202 results in a relevant tumor volume reduction and survival benefit, further pronounced with fractionated therapy vs single-dose treatment. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Radiopharm Theranostics, Ltd | Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗ |
| 2025-03-17 | Radiopharm Theranostics, Ltd | New RAD202 data confirms positive tumor uptake radiopharmtheranostics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-RAD202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06824155 ↗ |
| Modality | Protein / enzyme biologic | “a Lutetium-177 Radiolabeled Single Domain Antibody” NCT06824155 ↗ |